bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2
Receptor
Authors
E. Taka1‚Ä†, S. Z. Yilmaz1‚Ä†, M. Golcuk1‚Ä†, C. Kilinc1, U. Aktas1, A. Yildiz2,3, M. Gur1*
Affiliations
1

Department of Mechanical Engineering, Istanbul Technical University (ITU), Istanbul,

Turkey
2

Physics Department, University of California, Berkeley, CA, USA

3

Department of Molecular and Cellular Biology, University of California, Berkeley, CA, USA

* Corresponding author. Email: gurme@itu.edu.tr
‚Ä† These authors contributed equally to this work
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters human cells upon
binding of its spike (S) glycoproteins to ACE2 receptors and causes the coronavirus disease
2019 (COVID-19). Therapeutic approaches to prevent SARS-CoV-2 infection are mostly
focused on blocking S-ACE2 binding, but critical residues that stabilize this interaction are not
well understood. By performing all-atom molecular dynamics (MD) simulations, we identified
an extended network of salt bridges, hydrophobic and electrostatic interactions, and hydrogen
bonding between the receptor-binding domain (RBD) of the S protein and ACE2. Mutagenesis
of these residues on the RBD was not sufficient to destabilize binding but reduced the average
work to unbind the S protein from ACE2. In particular, the hydrophobic end of RBD serves as
the main anchor site and unbinds last from ACE2 under force. We propose that blocking this
site via neutralizing antibody or nanobody could prove an effective strategy to inhibit S-ACE2
interactions.

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Introduction
The COVID-19 pandemic is caused by SARS-CoV-2, which is a positive-sense single-stranded
RNA betacoronavirus. Phylogenetic analyses demonstrated that the SARS-CoV-2 genome
shares ~79% sequence identity with severe acute respiratory syndrome coronavirus (SARSCoV), and ~52% with the Middle-East respiratory syndrome coronavirus (MERS-CoV)1.
Despite these similarities, SARS-CoV-2 is much more infectious and fatal than SARS-CoV and
MERS-CoV together2.
SARS-CoV-2 consists of a 30 kb single-stranded RNA genome that is encapsulated by a lipid
bilayer and three distinct structural proteins that are embedded within the lipid membrane:
envelope (E), membrane (M), and spike (S). Host cell entry is primarily mediated by
homotrimeric S glycoproteins located on the viral membrane (Fig. 1a)3. Each S protomer
consists of S1 and S2 subunits that mediate binding to the host cell receptor and fusion of the
viral envelope, respectively3, 4. The receptor-binding domain (RBD) of S1 undergoes a large
rigid body motion to bind to ACE2. In the closed state, all RBDs of the S trimer are in the down
position, and the binding surface is inaccessible to ACE2. The switching of one of the RBDs
into a semi-open intermediate state is sufficient to expose the ACE2 binding surface and
stabilize the RBD in its up position (Fig. 1b)5.
The S protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, a
homodimeric integral membrane protein expressed in the epithelial cells of lungs, heart,
kidneys, and intestines6. Each ACE2 protomer consists of an N-terminal peptidase domain
(PD), which interacts with the RBD of the S protein through an extended surface (Fig. 1a, c)6,
7, 8

. Upon ACE2 binding, proteolytic cleavage of the S protein by the serine protease TMPRSS2

separates the S1 and S2 subunits9. The S2 protein exposes fusion peptides that insert into the
host membrane and promote fusion with the viral membrane4.
To prevent SARS-CoV-2 infection, there is a global effort to design neutralizing antibodies10,
nanobodies11, peptide inhibitors12, and small molecules13 that target the ACE2 binding surface
of the S protein. Yet, only a limited number of studies were performed to investigate critical
interactions that facilitate S-ACE2 binding using MD simulations. Initial studies have
constructed a homology model of SARS-CoV-2 RBD in complex with ACE2, based on the
SARS-CoV crystal structure8, 14 and performed conventional MD (cMD) simulations totaling
10 ns15, 16 and 100 ns17, 18 in length to estimate binding free energies15, 16 and interaction scores18.
More recent studies used the crystal structure of SARS-CoV-2 RBD in complex with ACE2 to
perform coarse-grained19 and all-atom20, 21, 22, 23 MD simulations. The effect of the mutations

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

that disrupt close contact residues between SARS-CoV-2 RBD and ACE2 on binding free
energy was investigated by post-processing of the MD trajectories15,

16, 21, 22

or by using

bioinformatic methods20. The work required to unbind the S protein from ACE2 would provide
a more accurate estimate of the binding strength, but this has not been performed under low
pulling velocities using the structure of SARS-CoV-2 RBD in complex with ACE2. In addition,
systematic analysis of critical residues that stabilize S-ACE2 binding and how mutagenesis of
these interaction sites reduces the binding strength and alters the way the S protein detaches
from ACE2 under force have not yet been performed.
In this study, we performed a comprehensive set of all-atom MD simulations totaling 16.5 ¬µs
in length using the recently-solved structure of the RBD of the SARS-CoV-2 S protein in
complex with the PD of ACE27. Simulations were performed in the absence and presence of
external force to investigate the binding characteristics and estimate the binding strength. These
simulations showed additional interactions between RBD and PD domains to those observed in
the crystal structure7. An extensive set of alanine substitutions and charge reversal mutations of
the RBD amino acids involved in ACE2 binding were performed to quantify how mutagenesis
of these residues weaken binding in the presence and absence of force in simulations. We
showed that the hydrophobic end of RBD primarily stabilizes S-ACE2 binding, and targeting
this site could potentially serve as an effective strategy to prevent SARS-CoV-2 infection.
Results
Interaction sites between the S protein and ACE2. To model the dynamic interactions of the
S-ACE2 binding interface, we used the co-structure of RBD of the SARS-CoV-2 S protein in
complex with the PD of human ACE27 (Fig. 1c). The structure was solvated in a water box that
contains physiologically-relevant salt (150 mM NaCl) concentration. Two sets of cMD
simulations, each of 100 ns in length, were performed to determine the formation of a salt
bridge24 and a hydrogen bond, as well as electrostatic and hydrophobic interactions between
RBD and PD (Supplementary Table 1). A cutoff distance of 6 √Ö between the basic nitrogens
and acidic oxygens was used to score a salt bridge formation24. For hydrogen bond formation,
a maximum 3.5 √Ö distance between hydrogen bond donor and acceptor and a 30¬∞ angle between
the hydrogen atom, the donor heavy atom, and the acceptor heavy atom was used25. Interaction
pairs that satisfy the distance, but not the angle criteria were analyzed as electrostatic
interactions. For hydrophobic interactions, a cutoff distance of 8 √Ö between the side chain
carbon atoms was used26,

27, 28

. Using these criteria, we identified eleven hydrophobic

interactions (Fig. 2a), eight hydrogen bonds (Fig. 2b), two salt bridges and six electrostatic
interactions (Fig. 2c) between RBD and PD. Observation frequencies were classified as high
3

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

and moderate for interactions that occur in 49% and above and between 15-48% of the total
trajectory, respectively. F486 and Y489 of RBD formed hydrophobic interactions with F28,
L79, M82, and Y83 of PD, while L455, F456, Y473, and A475 of RBD formed hydrophobic
interactions with T27 of PD at high frequencies (Fig. 2d). Salt bridges between K417-D30
(RBD-PD) and E484-K31, and hydrogen bonds between N487-Y83, T500-D355, and Q493E35 were observed at high frequencies, whereas hydrogen bonds Y449-D38, Q498-K353,
T500-Y41, Y505-E37, and Q493-E35 were observed at moderate frequencies (Fig. 2d).
Residue pairs Y453-H34, N487-Q24, T500-Y41, N501-K353, Q493-K31, and Y449-Q42
exhibited electrostatic interactions throughout the simulations (Fig. 2d).
The interaction network we identified in our cMD simulations were mostly consistent with
reported interactions in the RBD-PD crystal structure7. However, our simulations identified
four hydrogen bonds (Q498-K353, T500-D355, Y505-E37, and Q498-Q42), one hydrophobic
interaction (L455-T27), and two electrostatic interactions (Y453-H34 and N501-K353) that are
not present in the crystal structure. In turn, we did not detect frequent hydrogen bonding
between G446-Q42, G502-K353, and Y505-R393 and an electrostatic interaction between
G496-K353 observed in the crystal structure7. This discrepancy may be due to radically
different thermodynamic conditions between crystallization solutions and cMD simulations29.
We divided the RBD-PD interaction surface into three contact regions (CR1-3, Fig 2A-C)23.
The contact region 2 (CR2) comprised significantly fewer interactions than the ends of the RBD
binding surface (CR1 and CR3). Remarkably, 10 out of 13 interactions we detected in CR1
were hydrophobic, which were proposed to play a central role in anchoring of RBD to PD23.
Unlike CR1, CR2 formed only a single hydrophobic interaction with PD, whereas CR3 did not
form any hydrophobic interactions.
Unbinding of the S protein from ACE2 under force. To estimate the binding strength of the
S protein to ACE2, we performed steered MD (SMD) simulations to pull RBD away from PD
at a constant velocity of 2 √Ö ùëõùë† ‚àí1 along the vector pointing away from the binding interface
(Fig. 3a). Steering forces were applied to the CŒ± atoms of the RBD residues on the binding
interface, whereas CŒ± atoms of PD residues at the binding interface were kept fixed. These
simulations were also repeated in the absence of ACE2 to account for the work done against
viscous drag of water (Supplementary Fig. 1). The calculated average work against viscous
drag was subtracted from all SMD work values reported in this study. Because part of the work
applied is lost to the irreversible processes as we pull RBD away from PD at a finite velocity,
the second law of thermodynamics indicates that unbinding free energy difference between the
initial and final states cannot be larger than the average work required for unbinding. Therefore,
4

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

our calculations report relative changes in the binding free energy of wild-type (WT) and mutant
RBD under the same velocity and thermodynamic conditions. In 20 SMD simulations (each 15
ns, totaling 300 ns in length, Supplementary Table 1), the average work applied to unbind
SARS-CoV-2 RBD from PD was 64.0 ¬± 6.0 kcal/mol (mean ¬± s.d.), demonstrating that the S
protein binds stably to ACE2 (Fig. 3b).
Mutagenesis of the S-ACE2 binding interface. To investigate the contribution of each of the
16 interactions we identified to the overall binding strength, we introduced point mutations on
the RBD. Salt bridges were eliminated by charge reversals (K417E and E484K). We also
replaced each interaction amino acid (except A475) with alanine (Supplementary Table 1) to
disrupt the pairwise interactions30, with minimal perturbations the protein backbone31. Two sets
of cMD simulations (a total of 3.4 ¬µs in length) were performed for each point mutant. We first
quantified the root mean square fluctuation (RMSF) of the CŒ± atom of the RBD residues located
on the PD binding surface (Fig. 3c). The rigid body motions were eliminated by aligning the
RBD interaction surface of PD for each conformer (see Methods). 13 out of 17 mutations
increased the residue fluctuations compared to WT (Supplementary Fig. 2a), suggesting that
disrupting the interactions between RBD and PD results in floppier binding. Largest
fluctuations were observed for 2 mutations in CR1 (F486A, and N487A), 2 mutations in CR3
(Y449A and Y505A) and 1 mutation in CR2 (L455A) (Fig. 3c). Mutation of these residues also
increased the fluctuations in their neighboring region. While mutations in CR1 increased
fluctuations in CR3 significantly, mutations in CR3 had little to no effect on the fluctuations in
CR1 (Fig. 3d and Supplementary Fig. 2b).
We next performed SMD simulations modeling the unbinding of RBD of each point mutant
from PD (20 simulations for each mutant, a total of 5.1 ¬µs in length, Supplementary Table 1).
F486A, Y489A, N487A, Y473A, E484K and Y505A mutations decreased the work
requirement to unbind RBD-PD by 9-15% (Fig. 3e, f and Supplementary Fig. 3). We note that
most of these mutations also led to the largest increase in residue fluctuations on the binding
surface (Fig. 3c). 5 of these residues (F486, Y489, N487, Y473, and E484) are located in CR1,
whereas Y505 is located in CR3. These results highlight the primary role of hydrophobic
interactions in CR1 to stabilize the S-ACE2 binding.
To further characterize critical interactions of the S-ACE2 binding interface, we introduced
double mutants to neighboring residues of RBD that form critical interactions with PD. We
performed a total of 2.8 ¬µs of cMD and 4.2 ¬µs of SMD simulations for 14 double mutants
(Supplementary Table 1). In particular, double mutants in CR1 resulted in 4 out of the 6 highest
increase in RMSF (Fig. 4a and Supplementary Fig. 2). The F486A/N487A mutation at CR1
5

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

resulted in the largest increase in fluctuations in both CR1 and CR3 (Fig. 4a and Supplementary
Fig. 2). In SMD simulations, 12 out of 14 double mutations also further decreased the average
work to unbind RBD from PD (Fig. 4c, d and Supplementary Fig. 4). Similar to the RMSF
analysis, double mutants in CR1 (F486A/N487A, E484A/Y489A, E484A/F486A, and
L455A/F456A) resulted in 4 out of the 6 largest decreases in average work (Fig. 4d). A charge
reversal of K417E in combination with either Q493A or Y453A also resulted in a large decrease
in work values (Fig. 4d). We also used Jarzynski equality32, 33 to construct the free energy
profiles as a function of a reaction coordinate, referred to as the potential of mean force (PMF)34.
Based on the estimated PMF (Supplementary Fig. 5), double mutants in CR1 resulted in the
largest decrease in the binding energy by 31-21% compared to WT. Collectively, these results
show that two salt bridges (E484-K31 and K417-D30) and the network of hydrophobic
interactions in CR1 involving F486, Y489, Y473 and F456 residues are the most significant
contributors of binding strength between the S protein and ACE2.
The hydrophobic end of RBD serves as the main anchor site for ACE2 binding. To test
whether CR1 anchors RBD to PD23, we investigated the order of events that result in
detachment of RBD from PD in SMD simulations. The unbinding process appears to perform
a zipper-like detachment starting from CR3 and ending at CR1 in 85% of the simulations (Fig.
5a). In only 15% of the simulations, CR3 released last from PD (Fig. 5a). Because unbinding
simulations can reveal features characteristic for the reverse process of binding35, 36, 37, 38, 39,
these results suggest that CR1 binding is the first and critical event for the S protein binding to
ACE2. Mutagenesis of the critical residues in CR1, in general, resulted in a substantial decrease
in the percentages of unbinding events that terminate with the release of CR1 from PD. In
alanine replacement of the hydrophobic residues (F486A, F487, and Y489), CR1 was released
last for 60%, 55%, and 65% of the SMD simulations, respectively (Fig. 5b). The probability of
CR1 to release last under force was further reduced in double mutants of E484A/F486A (50%)
and L455A/F456A (55%) (Fig. 5b). Unlike these mutants, F456A and E484K mutants in CR1
increased the probability of CR1 to release last, but this could be attributed to a large increase
in fluctuations in CR3 upon these mutations (Supplementary Fig. 2b). These results indicate
that single and double mutants of the critical residues in CR1 substantially reduce the binding
free energy of this region to ACE2.
S proteins of SARS-CoV-2 and SARS-CoV have similar binding strength to ACE2. It
remains unclear whether higher infectivity of SARS-CoV-2 than SARS-CoV can be attributed
to stronger interactions between S and ACE2 in SARS-CoV-22, 15. To test this possibility, we
performed two sets of MD simulations for the RBD of SARS-CoV S protein bound to the PD
6

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

of ACE2 (PDB ID: 2AJF8), and compared these results to that of SARS-CoV-2. Similar to
SARS-CoV-2, RBD of SARS-CoV makes an extensive network of interactions with PD. We
identified eleven hydrophobic interactions (Fig. 6a), six hydrogen bonds (Fig. 6b), and seven
electrostatic interactions (Fig. 6c). Out of these 15 interactions, only 6 are conserved in SARSCoV and the following mutations have taken place: L443/F456 (SARS-CoV/SARS-CoV-2),
F460/Y473, P462/A475, P470/E484, L472/F486 V404/K417, N479/Q493, Y484/Q498, and
T487/N501. Similar to SARS-CoV-2, L472 and Y475 of SARS-CoV RBD formed a total of
seven hydrophobic interactions at a high frequency with the hydrophobic pocket of ACE2 (Fig.
6d). Unlike SARS-CoV-2, SARS-CoV RBD did not form any salt bridges with ACE2.
We next modeled the unbinding of RBD of SARS-CoV from PD by performing 20 SMD
simulations (totaling 300 ns in length, Supplementary Table 1). The average total unbinding
work of SARS-CoV (64.5 ¬± 12.2 kcal/mol, mean ¬± s.d., Fig. 6e) was identical but more broadly
distributed than that of SARS-CoV-2 (64.0 ¬± 6.0 kcal/mol, Fig. 3b). Unlike SARS-CoV-2, CR1
released last from PD in only 40% of the unbinding events of RBD of SARS-CoV, whereas the
unbinding of CR3 was the last event in the remaining 60% (Fig. 6f). These results indicate that
the S protein binds stably to ACE2 in both SARS-CoV and SARS-CoV-2 and the higher
infectivity of SARS-CoV-2 cannot be explained by an increase in binding strength. Higher
variability in unbinding work values and the absence of a clear order in unbinding events of
RBD of SARS-CoV suggest that SARS-CoV has a more variable binding mechanism to ACE2
than SARS-CoV-2.
Discussion
We performed an extensive set of in silico analysis to identify critical residues that facilitate
binding of the RBD of the SARS-CoV-2 S protein to the human ACE2 receptor. Mutagenesis
of these residues and pulling the RBD away from PD at a low velocity enabled us to estimate
the free energy of binding and the order of events that result in the unbinding of RBD from PD.
Our simulations showed that the PD interacting surface of RBD can be divided into three
contact regions (CR1-3). Hydrophobic residues of CR1 strongly interact with the hydrophobic
pocket of PD in both SARS-CoV and SARS-CoV-2. CR1 of SARS-CoV-2 also forms a salt
bridge with ACE2 that is not present in SARS-CoV. Based on our SMD simulations, we did
not observe a major difference in binding strength of the S protein to ACE2 between SARSCoV and SARS-CoV-2, indicating that higher infectivity of SARS-CoV-2 is not due to tighter
binding of S to the ACE2 receptor. These results are consistent with a recent MD simulation
that applied the generalized Born and surface area continuum solvation approach (MMGBSA)22, coarse-grained simulations19, and biolayer interferometry2.
7

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Our analysis suggests that CR1 is the main anchor site of the SARS-CoV-2 S protein to ACE2,
and blocking the CR1 residues F456, Y473, E484, F486, N487, and Y489 could significantly
reduce the binding affinity. Consistent with this prediction, llama based nanobodies H11-H4
and H11-D4 neutralize SARS-CoV-211 by each interacting with 50% of the critical residues we
identified in each of CR1 and CR2. Furthermore, alpaca based nanobody Ty1 was shown to
neutralize SARS-CoV-240 and among its primary interactions are E484 in CR1, and Q493 and
Y449 in CR3, which were also determined as critical residues in our study. Similarly, the human
neutralizing antibodies CV3041, B3841, CB641, and VH3-5342, 43 are interacting with 50-100%
of the critical residues identified in our study.
Experimental studies revealed that antibodies against SARS-CoV induce limited neutralizing
activity against SARS-CoV-210, 23. This may be attributed to the low sequence conservation of
the CR1 region between SARS-CoV and SARS-CoV-2. In particular, the S protein of SARSCoV-2 contains critical phenylalanine (F486) and glutamate (E484) residues not present in
SARS-CoV, that form hydrophobic interactions and a salt bridge with ACE2, respectively. It
remains to be determined whether this difference plays a role in higher infectivity of SARSCoV-2 than SARS-CoV.
Our simulations show that single and double mutants of CR1 are not sufficient to disrupt the
binding of RBD to ACE2, but reduce the binding free energy of this region. Because RBD
makes multiple contacts with ACE2 through an extended surface, small molecules or peptides
that target a specific region in the RBD-ACE2 interaction surface may not be sufficient to
prevent binding of the S protein to ACE2. Instead, blocking of a larger surface of the CR1
region with a neutralizing antibody or nanobody is more likely to introduce steric constraints to
prevent the S-ACE2 interactions.
Methods
MD simulations system preparation. For cMD simulations, the crystal structure of SARSCoV-2 S protein RBD bound with ACE2 at 2.45 √Ö resolution (PDB ID: 6M0J)7 was used as a
template. The chloride ion, zinc ion, glycans, and water molecules in the crystal structure were
kept in their original positions. Single and double point mutants were generated using the
Mutator Plugin in VMD44. Each system was solvated in a water box (using the TIP3P water
model) having 35 √Ö cushion in the positive x-direction and 15 √Ö cushions in other directions.
This puts a 50 √Ö water cushion between the RBD-PD complex and its periodic image in the xdirection, creating enough space for unbinding simulations. Ions were added to neutralize the
system and salt concentration was set to 150 mM to construct a physiologically relevant

8

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

environment. The size of each solvated system was ~164,000 atoms. All system preparation
steps were performed in VMD44.
Conventional MD simulations. All MD simulations were performed in NAMD 2.1345 using
the CHARMM3646 force field with a time step of 2 fs. MD simulations were performed under
N, P, T conditions. The temperature was kept at 310 K using Langevin dynamics with a
damping coefficient of 1 ps-1. The pressure was maintained at 1 atm using the Langevin Nos√©Hoover method with an oscillation period of 100 fs and a damping time scale of 50 fs. Periodic
boundary conditions were applied. 12 √Ö cutoff distance was used for van der Waals interactions.
Long-range electrostatic interactions were calculated using the particle-mesh Ewald method.
For each system; first, 10,000 steps of minimization followed by 2 ns of equilibration was
performed by keeping the protein fixed. The complete system was minimized for additional
10,000 steps, followed by 4 ns of equilibration by applying constraints on C Œ± atoms.
Subsequently, these constraints were released and the system was equilibrated for an additional
4 ns before initiating the production runs. The length of the equilibrium steps is expected to
account for the structural differences due to the radically different thermodynamic conditions
of crystallization solutions and MD simulations29. MD simulations were performed in Comet
and Stampede2 using ~8 million core-hours in total.
RMSF calculations. RMSF values were calculated as ‚å©‚àÜùëÖùëñ2 ‚å™1/2 = ‚å©(ùëÖùëñ ‚àí ‚å©ùëÖùëñ ‚å™ )2 ‚å™1/2, where,
‚å©ùëÖùëñ ‚å™ is the mean atomic coordinate of the ith CŒ± atom and ùëÖùëñ is its instantaneous coordinate.
SMD simulations. SMD47 simulations were used to explore the unbinding process of RBD
from ACE2 on time scales accessible to standard simulation lengths. SMD simulations have
been applied to explore a wide range of processes, including domain motion5, 48, molecule
unbinding49, and protein unfolding50. In SMD simulations, a dummy atom is attached to the
center of mass of ‚Äòsteered‚Äô atoms via a virtual spring and pulled at constant velocity along the
‚Äòpulling direction‚Äô, resulting in force F to be applied to the SMD atoms along the pulling
vector45,
ùêÖ = ‚àí‚àáùëà

(1)

1
ùëà = ùëò[ùêØùë° ‚àí (ùêë ‚àí ùêë 0 ) ‚àô ùêß]2
2

(2)

where ùëà is the guiding potential, ùëò is the spring constant, ùêØ is the pulling velocity, ùë° is time,
ùêë and ùêë 0 are the coordinates of the center of mass of steered atoms at time t and 0, respectively,
and ùêß is the direction of pulling45. Total work (W) performed for each simulation was evaluated
ùúâ

by integrating F over displacement ùúâ along the pulling direction as ùëä = ‚à´0 ùêπ(ùúâ)ùëëùúâ .

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

In SMD simulations of SARS-CoV-2, CŒ± atoms of ACE2 residues S19-S43, T78-P84, Q325N330, G352-I358, and P389-R393 were kept fixed, whereas CŒ± atoms of RBD residues K417I418, G446-F456, Y473-A475, and N487-Y505 were steered (Fig. 3a). Steered atoms were
selected as the region comprising the interacting residues. For SARS-CoV SMD simulations
the same ACE2 residues were kept fixed. However, two slightly different steered atoms
selections were applied: i) Using the same residue positions as for SARS-CoV-2, which are
V404-I405, T433-L443, F460-S461, and N473-Y491, and ii) selecting the region comprising
the interacting residues, which areT433-L443, F460-D463, and N473-Y491. The total number
of fixed and steered atoms were identical in all simulations. The pulling direction was selected
as the vector pointing from the center of mass of fixed atoms to the center of mass of steered
atoms. The pulling direction also serves as the reaction coordinate Œæ for free energy calculations.
Each SMD simulation was performed for 15 ns using a 2 √Ö ùëõùë† ‚àí1 pulling velocity. At a spring
constant of 100 ùëòùëêùëéùëô ùëöùëúùëô ‚àí1 √Ö ‚àí2 , the center of mass of the steered atoms followed the dummy
atom closely while the spring was still soft enough to allow small deviations. For each system,
20 conformations were sampled with a 10 ns frequency from their cMD simulations (10
conformers from each set of the cMD simulations listed in Supplementary Table 1 MD1-33 ab). These conformations served as 20 separate starting conformations, ùêë 0 , for each set of SMD
simulations (Supplementary Table 1 MD1-33 c-d).
Potential of mean force for unbinding of RBD. Work values to unbind RBD from ACE2 at
low pulling velocities along the reaction coordinate were analyzed using Jarzynski equality,
which provides a relation between equilibrium free energy differences and the work performed
through non-equilibrium processes32, 33, 34:
ùëí ‚àí‚àÜùêπ/ùëòùêµ ùëá = ‚å©ùëí ‚àíùëä/ùëòùêµ ùëá ‚å™

(3)

where ŒîF is the Helmholtz free energy, kB is the Boltzmann constant and T is the temperature.
Because work values sampled in our SMD simulations differ more than1 kBT (Supplementary
Figs. 3,4), the average work calculated in equation (3) will be dominated by small work values
that are only rarely sampled. For a finite (N) number of SMD simulations, the term
‚àíùëäùëñ /ùëòùêµ ùëá ‚ÅÑ
‚àíùëòùêµ ùëáln(‚àëùëÅ
ùëÅ) did not converge to ‚å©ùëí ‚àíùëä/ùëòùêµ ùëá ‚å™. Thus, equation (3) provides an
ùëñ=1 ùëí

upper bound on ŒîF, which was used as an estimate of the PMF.
Data availability
Data and the analysis software are available from the corresponding author upon request.

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

References
1.

Ren L-L, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive
study. Chinese medical journal, (2020).

2.

Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and
Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, (2020).

3.

Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by
the viral spike protein. Viruses 4, 1011-1033 (2012).

4.

Kirchdoerfer RN, et al. Stabilized coronavirus spikes are resistant to conformational changes induced by
receptor recognition or proteolysis. Scientific reports 8, 1-11 (2018).

5.

Gur M, Taka E, Yilmaz SZ, Kilinc C, Aktas U, Golcuk M. Conformational transition of SARS-CoV-2
spike glycoprotein between its closed and open states. The Journal of Chemical Physics 153, 075101
(2020).

6.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2
by full-length human ACE2. Science, (2020).

7.

Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature, 1-9 (2020).

8.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain
complexed with receptor. Science 309, 1864-1868 (2005).

9.

Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
clinically proven protease inhibitor. Cell, (2020).

10.

Yi C, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact
with ACE2 and neutralizing antibodies. Cellular & Molecular Immunology, 1-10 (2020).

11.

Huo J, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Nature Structural & Molecular Biology, (2020).

12.

Han Y, Kr√°l P. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2. ACS nano,
(2020).

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

13.

de Oliveira OV, Rocha GB, Paluch AS, Costa LT. Repurposing approved drugs as inhibitors of SARSCoV-2 S-protein from molecular modeling and virtual screening. Journal of Biomolecular Structure and
Dynamics, 1-14 (2020).

14.

Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in
complex with its host cell receptor ACE2. PLoS pathogens 14, e1007236 (2018).

15.

He J, Tao H, Yan Y, Huang S-Y, Xiao Y. Molecular Mechanism of Evolution and Human Infection with
SARS-CoV-2. Viruses 12, 428 (2020).

16.

Armijos‚ÄêJaramillo V, Yeager J, Muslin C, Perez‚ÄêCastillo Y. SARS‚ÄêCoV‚Äê2, an evolutionary perspective
of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability.
Evolutionary Applications, (2020).

17.

Zou J, et al. Computational Prediction of Mutational Effects on the SARS-CoV-2 Binding by Relative
Free Energy Calculations. (2020).

18.

Brielle ES, Schneidman-Duhovny D, Linial M. The SARS-CoV-2 exerts a distinctive strategy for
interacting with the ACE2 human receptor. Viruses 12, 497 (2020).

19.

Bai C, Warshel A. Critical Differences Between the Binding Features of the Spike Proteins of SARSCoV-2 and SARS-CoV. The Journal of Physical Chemistry B 124, 5907-5912 (2020).

20.

Dehury B, Raina V, Misra N, Suar M. Effect of mutation on structure, function and dynamics of receptor
binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations
study. Journal of Biomolecular Structure and Dynamics, 1-15 (2020).

21.

Ali A, Vijayan R. Dynamics of the ACE2‚ÄìSARS-CoV-2/SARS-CoV spike protein interface reveal
unique mechanisms. Scientific Reports 10, 1-12 (2020).

22.

Li Y, et al. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike.
Iscience, 101160 (2020).

23.

Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogenbonding and hydrophobic interactions. Proceedings of the National Academy of Sciences, (2020).

24.

Beckstein O, Denning EJ, Perilla JR, Woolf TB. Zipping and unzipping of adenylate kinase: atomistic
insights into the ensemble of open‚Üî closed transitions. Journal of molecular biology 394, 160-176
(2009).

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

25.

Durrant JD, McCammon JA. HBonanza: a computer algorithm for molecular-dynamics-trajectory
hydrogen-bond analysis. Journal of Molecular Graphics and Modelling 31, 5-9 (2011).

26.

Stock P, Utzig T, Valtiner M. Direct and quantitative AFM measurements of the concentration and
temperature dependence of the hydrophobic force law at nanoscopic contacts. Journal of colloid and
interface science 446, 244-251 (2015).

27.

Manavalan P, Ponnuswamy P. A study of the preferred environment of amino acid residues in globular
proteins. Archives of biochemistry and biophysics 184, 476-487 (1977).

28.

Stavrakoudis A, Tsoulos IG, Shenkarev ZO, Ovchinnikova TV. Molecular Dynamics Simulation of
Antimicrobial Peptide Arenicin-2: b-Hairpin Stabilization by Noncovalent Interactions.

29.

Pullara F, Wenzhi M, G√úR M. Why protein conformers in molecular dynamics simulations differ from
their crystal structures: a thermodynamic insight. Turkish Journal of Chemistry 43, 394-403 (2019).

30.

Weiss GA, Watanabe CK, Zhong A, Goddard A, Sidhu SS. Rapid mapping of protein functional epitopes
by combinatorial alanine scanning. Proceedings of the National Academy of Sciences 97, 8950-8954
(2000).

31.

Bradshaw RT, Patel BH, Tate EW, Leatherbarrow RJ, Gould IR. Comparing experimental and
computational alanine scanning techniques for probing a prototypical protein‚Äìprotein interaction. Protein
Engineering, Design & Selection 24, 197-207 (2011).

32.

Jarzynski C. Equilibrium free-energy differences from nonequilibrium measurements: A master-equation
approach. Physical Review E 56, 5018 (1997).

33.

Jarzynski C. Nonequilibrium equality for free energy differences. Physical Review Letters 78, 2690
(1997).

34.

Park S, Khalili-Araghi F, Tajkhorshid E, Schulten K. Free energy calculation from steered molecular
dynamics simulations using Jarzynski‚Äôs equality. The Journal of chemical physics 119, 3559-3566
(2003).

35.

Le L, Lee EH, Hardy DJ, Truong TN, Schulten K. Molecular dynamics simulations suggest that
electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases. PLoS Comput Biol 6,
e1000939 (2010).

36.

Izrailev S, Stepaniants S, Balsera M, Oono Y, Schulten K. Molecular dynamics study of unbinding of the
avidin-biotin complex. Biophysical journal 72, 1568-1581 (1997).

13

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

37.

Yang L-J, Zou J, Xie H-Z, Li L-L, Wei Y-Q, Yang S-Y. Steered molecular dynamics simulations reveal
the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. PLoS One 4, e8470
(2009).

38.

Liu X, Xu Y, Wang X, Barrantes FJ, Jiang H. Unbinding of nicotine from the acetylcholine binding
protein: steered molecular dynamics simulations. The Journal of Physical Chemistry B 112, 4087-4093
(2008).

39.

Shen J, Li W, Liu G, Tang Y, Jiang H. Computational insights into the mechanism of ligand unbinding
and selectivity of estrogen receptors. The Journal of Physical Chemistry B 113, 10436-10444 (2009).

40.

Hanke L, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nature
Communications 11, 4420 (2020).

41.

Hurlburt NK, et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity
maturation. Nature communications 11, 1-7 (2020).

42.

Barnes CO, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature,
(2020).

43.

Wu NC, et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding
domain. Cell reports 33, 108274 (2020).

44.

Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. Journal of molecular graphics
14, 33-38 (1996).

45.

Phillips JC, et al. Scalable molecular dynamics with NAMD. Journal of computational chemistry 26,
1781-1802 (2005).

46.

Best RB, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved
sampling of the backbone œï, œà and side-chain œá1 and œá2 dihedral angles. Journal of chemical theory and
computation 8, 3257-3273 (2012).

47.

Isralewitz B, Gao M, Schulten K. Steered molecular dynamics and mechanical functions of proteins.
Current opinion in structural biology 11, 224-230 (2001).

48.

Izrailev S, Crofts AR, Berry EA, Schulten K. Steered molecular dynamics simulation of the Rieske
subunit motion in the cytochrome bc1 complex. Biophysical journal 77, 1753-1768 (1999).

14

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

49.

Eskici G, Gur M. Computational design of new peptide inhibitors for amyloid beta (AŒ≤) aggregation in
Alzheimer's disease: application of a novel methodology. Plos one 8, (2013).

50.

Lu H, Isralewitz B, Krammer A, Vogel V, Schulten K. Unfolding of titin immunoglobulin domains by
steered molecular dynamics simulation. Biophysical journal 75, 662-671 (1998).

51.

Casalino L, et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS
Central Science 6, 1722-1734 (2020).

Acknowledgments
We gratefully acknowledge the support of the COVID-19 HPC Consortium (Grant number:
TG-MCB200070), and Extreme Science and Engineering Discovery Environment (XSEDE).
Author contributions
Mert Gur (M.G.) and A.Y. initiated the project. M.G. supervised the project. E.T., S.Z.Y., Mert
Golcuk (M.Go), C.K., U.A., and M.G. performed molecular dynamics simulations. E.T.,
S.Z.Y., M.Go, C.K., U.A., A.Y., and M.G. prepared the manuscript.
Competing interests
The authors declare no competing interests.

15

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figures

Fig. 1. Atomic model for binding of the SARS-CoV-2 S protein to the ACE2 receptor on
the host cell membrane. a The structure of the full-length S protein in complex with ACE2.
The S protein is a homotrimer (green, purple, and grey) and embedded into the viral membrane.
ACE2 is a homodimer (blue and orange) and embedded into the host cell membrane. The full
length structure of the S protein in complex with ACE2 was modeled using the full length S
protein model 51 and the crystal structure of the S protein RBD in complex with ACE2 (PDB
ID: 6M17). Both proteins were manually inserted into the membrane by their transmembrane
domains. b The structure of an S protomer in the down and up position of its RBD. S1/S2 and
S2‚Äô are the cleavage sites of the S protomer upon ACE2 binding. (C) MD simulations were
performed for RBD of the S protein in complex with the PD of ACE2. Catalytic residues of
ACE2, glycans, and Zn+2 and Cl- ions are shown in brown, red, yellow and purple, respectively.

16

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. 2. Interactions between RBD of the SARS-CoV-2 S protein and PD of ACE2. a
Hydrophobic interactions b Hydrogen bonds, and c Salt bridges and electrostatic interactions,
between RBD (green) and PD (blue) are shown on a conformation obtained from MD
simulations in the left panels. The interaction surface is divided into three distinct regions (CR13). Normalized distributions of the distances between the amino-acid pairs that form
hydrophobic interactions (red), hydrogen bonds (purple), salt bridges (orange), and electrostatic
interactions (green) are shown in the right panels. Lines with colored numbers represent
17

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

maximum cutoff distances for these interactions. d The frequencies and mean distances of the
pairwise interactions of the RBD-PD binding interface. Error bars represent s.d.

Fig. 3. Point mutations in the ACE2 binding surface of RBD reduce the binding strength.
a In SMD simulations, CŒ± atoms of PD residues (yellow) were fixed, whereas CŒ± atoms of RBD
(purple) were steered. The orange arrow on the RBD (green) shows the SMD pulling vector,

18

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

which was taken as the reaction coordinate. b Distribution of work applied during unbinding of
RBD from PD. The thick line represents the average work values. c RMSF of RBD residues
located on the PD binding surface of WT and point mutants. d Point mutants in CR1, CR2 and
CR3 alter the RMSF values of the CŒ± atoms of CR1, CR2 and CR3 regions relative to WT. e
Over 20 SMD simulations, the average work required to move RBDs along the reaction
coordinate are shown for the WT and point mutants. Work profiles in the region ùúâ = 29 ‚Äì 30 √Ö
are shown on the right panel. f The change in the average unbinding work of point mutants
compared to WT. P values were calculated using a two-tailed Student‚Äôs t-test. P values larger
than 0.05 are not shown. Error bars represent s.d.

19

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. 4. Double mutants of the PD binding surface of RBD more strongly decrease its
binding strength. a Residue fluctuations at the ACE2 binding surface for WT and double
mutants of the SARS-CoV-2 S protein. b Double mutants in CR1, CR2 and CR3 alter the RMSF
values of the CŒ± atoms of CR1, CR2 and CR3 regions relative to WT. c Over 20 SMD
simulations, the average work required to move RBD along the reaction coordinate is shown
for the WT and double mutants. Work profiles in the region ùúâ = 29 ‚Äì 30 √Ö are shown on the
right panel. d The change in the average unbinding work of double mutants compared to WT.
P values were calculated using a two-tailed Student‚Äôs t-test. Error bars represent s.d.

20

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. 5. CR1 releases last from PD under force. a (Top left) Representative conformer shows
CR1 releases last when RBD was pulled away from PD at a constant velocity of 2 √Ö/ns. (Top
right) Displacement of the critical residues in CR1 (yellow), CR2 (blue), and CR3 (red) along
21

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

the reaction coordinate, averaged over 17 SMD simulations. (Bottom left) Representative
conformer shows CR3 releases last when RBD was pulled away from PD in SMD simulations.
(Bottom right) Displacement of the critical residues in CR1 (yellow), CR2 (blue), and CR3
(red) along the reaction coordinate, averaged over 3 SMD simulations. b The percentage of
SMD trajectories of WT and mutant RBD, in which CR1 released last from PD when pulled at
a constant velocity.

22

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. 6. Interactions between RBD of the SARS-CoV S protein and PD of ACE2. a
Hydrophobic interactions b Hydrogen bonds, and c Electrostatic interactions, between RBD
(orange) and PD (blue) are shown on a conformation obtained from MD simulations in the left
panels. Normalized distributions of the distances between the amino-acid pairs that form
23

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

hydrophobic interactions (red), hydrogen bonds (purple), and electrostatic interactions (green)
are shown in the right panels. Lines with colored numbers represent maximum cutoff distances
for these interactions. d The frequencies and mean distances of the pairwise interactions of the
SARS-CoV S protein and ACE2 binding interface. e Distribution of work applied during
unbinding of RBD from PD. The thick line represents the average work values. f (Left)
Representative conformer shows CR3 releases last when RBD was pulled away from PD at a
constant velocity of 2 «∫/ns. (Right) Displacement of the critical residues in CR1 (yellow), CR2
(blue), and CR3 (red) along the reaction coordinate, averaged over 12 SMD simulations. Error
bars represent s.d.

24

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Supplementary Materials

Fig. S1. Work done against viscous drag of water in SMD simulation. a In SMD
simulations, CŒ± atoms of RBD (purple) were steered. The orange arrow on the RBD (green)
shows the SMD pulling vector, which was taken as the reaction coordinate. b Work values
obtained from pulling RBD in the absence of ACE2. Black line is the average work from 10
different SMD simulations. Red line represents the work done against the viscous drag of SMD
simulation and was defined as the line passing through the initial and last data point of the black
curve. c Distribution of work values are shown for uncorrected (work values as obtained from
the SMD simulations) and corrected (work done against viscous drag of water is subtracted
from SMD work values) are shown. Thick line represents the mean work values.

25

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. S2. RMSF values of single and double mutants of RBD of SARS-CoV-2. a RMSF of
RBD residues located on the PD binding surface of WT and point mutants. b Average RMSF
values of the CŒ± atoms at CR1, CR2, and CR3 for the WT and mutant SARS-CoV-2 RBD in
complex with ACE2 PD. The black lines in each bar show the average RMSF values in CR1,
CR2, and CR3 for the WT. Error bars represent s.d.

26

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. S3. Distribution of work values obtained from SMD simulations for each single point
mutant system of RBD of SARS-CoV-2. Thick lines represent the average work values of
each system.

27

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. S4. Distribution of work values obtained from SMD simulations for each double point
mutant system of RBD of SARS-CoV-2. Thick lines represent the average work values of
each system.

28

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. S5. PMF and ŒîF values of WT and six point mutants of RBD of SARS-CoV-2. a PMF
values of WT and 6 double mutants with lowest unbinding work values. b ŒîF values of these
mutants are calculated from Jarzynski equality.

29

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Table S1. Starting conformations and durations of the MD simulations performed.
Simulation
Run
Simulation
Initial state
RBD sequence
Duration
ID
Type
(ns)
1a-b
RBD-ACE2 complex (6M0J)
WT SARS-CoV-2
MD
(a) 100, (b) 100
1c-d
Final conformers of MD 1a-b
WT SARS-CoV-2
SMD
(c) 150, (d) 150
2a-b
RBD-ACE2 complex (6M0J)
K417A
MD
(a) 100, (b) 100
2c-d
Final conformers of MD 2a-b
K417A
SMD
(c) 150, (d) 150
3a-b
RBD-ACE2 complex (6M0J)
K417E
MD
(a) 100, (b) 100
3c-d
Final conformers of MD 3a-b
K417E
SMD
(c) 150, (d) 150
4a-b
RBD-ACE2 complex (6M0J)
E484A
MD
(a) 100, (b) 100
4c-d
Final conformers of MD 4a-b
E484A
SMD
(c) 150, (d) 150
5a-b
RBD-ACE2 complex (6M0J)
E484K
MD
(a) 100, (b) 100
5c-d
Final conformers of MD 5a-b
E484K
SMD
(c) 150, (d) 150
6a-b
RBD-ACE2 complex (6M0J)
Y489A
MD
(a) 100, (b) 100
6c-d
Final conformers of MD 6a-b
Y489A
SMD
(c) 150, (d) 150
7a-b
RBD-ACE2 complex (6M0J)
N487A
MD
(a) 100, (b) 100
7c-d
Final conformers of MD 7a-b
N487A
SMD
(c) 150, (d) 150
8a-b
RBD-ACE2 complex (6M0J)
F486A
MD
(a) 100, (b) 100
8c-d
Final conformers of MD 8a-b
F486A
SMD
(c) 150, (d) 150
9a-b
RBD-ACE2 complex (6M0J)
Y505A
MD
(a) 100, (b) 100
9c-d
Final conformers of MD 9a-b
Y505A
SMD
(c) 150, (d) 150
10a-b RBD-ACE2 complex (6M0J)
Q453A
MD
(a) 100, (b) 100
10c-d Final conformers of MD 10a-b Q453A
SMD
(c) 150, (d) 150
11a-b RBD-ACE2 complex (6M0J)
T500A
MD
(a) 100, (b) 100
11c-d Final conformers of MD 11a-b T500A
SMD
(c) 150, (d) 150
12a-b RBD-ACE2 complex (6M0J)
Y449A
MD
(a) 100, (b) 100
12c-d Final conformers of MD 12a-b Y449A
SMD
(c) 150, (d) 150
13a-b RBD-ACE2 complex (6M0J)
Q493A
MD
(a) 100, (b) 100
13c-d Final conformers of MD 13a-b Q493A
SMD
(c) 150, (d) 150
14a-b RBD-ACE2 complex (6M0J)
Q498A
MD
(a) 100, (b) 100
14c-d Final conformers of MD 14a-b Q498A
SMD
(c) 150, (d) 150
15a-b RBD-ACE2 complex (6M0J)
N501A
MD
(a) 100, (b) 100
15c-d Final conformers of MD 15a-b N501A
SMD
(c) 150, (d) 150
16a-b RBD-ACE2 complex (6M0J)
L455A
MD
(a) 100, (b) 100
16c-d Final conformers of MD 16a-b L455A
SMD
(c) 150, (d) 150
17a-b RBD-ACE2 complex (6M0J)
F456A
MD
(a) 100, (b) 100
17c-d Final conformers of MD 17a-b F456A
SMD
(c) 150, (d) 150
18a-b RBD-ACE2 complex (6M0J)
Y473A
MD
(a) 100, (b) 100
18c-d Final conformers of MD 18a-b Y473A
SMD
(c) 150, (d) 150
19a-b RBD-ACE2 complex (6M0J)
F486A/N487A
MD
(a) 100, (b) 100
19c-d Final conformers of MD 19a-b F486A/N487A
SMD
(c) 150, (d) 150
20a-b RBD-ACE2 complex (6M0J)
E484A/Y489A
MD
(a) 100, (b) 100
20c-d Final conformers of MD 20a-b E484A/Y489A
SMD
(c) 150, (d) 150
21a-b RBD-ACE2 complex (6M0J)
E484A/F486A
MD
(a) 100, (b) 100
30

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.305490; this version posted November 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

21c-d
22a-b
22c-d
23a-b
23c-d
24a-b
24c-d
25a-b
25c-d
26a-b
26c-d
27a-b
27c-d
28a-b
28c-d
29a-b
29c-d
30a-b
30c-d
31a-b
31c-d
32a-b
32c-d
33a-b
33c-d

Final conformers of MD 21a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 22a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 23a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 24a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 25a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 26a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 27a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 28a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 29a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 30a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 31a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 32a-b
RBD-ACE2 complex (6M0J)
Final conformers of MD 33a-b

E484A/F486A
T500A/Y505A
T500A/Y505A
Y453A/K417E
Y453A/K417E
Q493A/Y453A
Q493A/Y453A
Q493A/K417E
Q493A/K417E
Y449A/Q498A
Y449A/Q498A
Y449A/Y505A
Y449A/Y505A
Q498A/T500A
Q498A/T500A
N501A/T500A
N501A/T500A
N501A/Q498A
N501A/Q498A
L455A/F456A
L455A/F456A
F456A/Y473A
F456A/Y473A
WT SARS-CoV
WT SARS-CoV

31

SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD
MD
SMD

(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150
(a) 100, (b) 100
(c) 150, (d) 150

